{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:12:34Z","timestamp":1788336754370,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Haleon"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sleep Breath"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11325-025-03328-w","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T18:48:32Z","timestamp":1744656512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effect of doxepin 3\u00a0mg on sleep latency: a pooled analysis of two phase 3 trials"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0014-4445","authenticated-orcid":false,"given":"Matt","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mako","family":"Araga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy","family":"Franks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"issue":"8","key":"3328_CR1","doi-asserted-by":"publisher","first-page":"997","DOI":"10.5665\/sleep.1150","volume":"34","author":"JK Walsh","year":"2011","unstructured":"Walsh JK, Coulouvrat C, Hajak G, Lakoma MD, Petukhova M, Roth T, Sampson NA, Shahly V, Shillington A, Stephenson JJ, Kessler RC (2011) Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). Sleep 34(8):997\u20131011. https:\/\/doi.org\/10.5665\/sleep.1150","journal-title":"Sleep"},{"issue":"2","key":"3328_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jsmc.2022.03.003","volume":"17","author":"CM Morin","year":"2022","unstructured":"Morin CM, Jarrin DC (2022) Epidemiology of insomnia: prevalence, course, risk factors, and public health burden. Sleep Med Clin 17(2):173\u2013191. https:\/\/doi.org\/10.1016\/j.jsmc.2022.03.003","journal-title":"Sleep Med Clin"},{"issue":"6","key":"3328_CR3","doi-asserted-by":"publisher","first-page":"zsz299","DOI":"10.1093\/sleep\/zsz299","volume":"43","author":"ML Perlis","year":"2020","unstructured":"Perlis ML, Vargas I, Ellis JG, Grandner MA, Morales KH, Gencarelli A, Khader W, Kloss JD, Gooneratne NS, Thase ME (2020) The natural history of insomnia: the incidence of acute insomnia and subsequent progression to chronic insomnia or recovery in good sleeper subjects. Sleep 43(6):zsz299. https:\/\/doi.org\/10.1093\/sleep\/zsz299","journal-title":"Sleep"},{"issue":"10","key":"3328_CR4","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jpsychires.2012.07.001","volume":"46","author":"JG Ellis","year":"2012","unstructured":"Ellis JG, Perlis ML, Neale LF, Espie CA, Bastien CH (2012) The natural history of insomnia: focus on prevalence and incidence of acute insomnia. J Psychiatr Res 46(10):1278\u20131285. https:\/\/doi.org\/10.1016\/j.jpsychires.2012.07.001","journal-title":"J Psychiatr Res"},{"issue":"5 suppl","key":"3328_CR5","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.5664\/jcsm.26929","volume":"3","author":"T Roth","year":"2007","unstructured":"Roth T (2007) Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 3(5 suppl):S7\u2013S10","journal-title":"J Clin Sleep Med."},{"key":"3328_CR6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and statistical manual of mental disorders, Fifth Edition, Text Revision","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association (2022) Diagnostic and statistical manual of mental disorders, Fifth Edition, Text Revision. American Psychiatric Association, Washington, DC"},{"issue":"1","key":"3328_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0022-3999(02)00547-0","volume":"54","author":"ML Perlis","year":"2003","unstructured":"Perlis ML, Smith MT, Cacialli DO, Nowakowski S, Orff H (2003) On the comparability of pharmacotherapy and behavior therapy for chronic insomnia. Commentary and implications J Psychosom Res 54(1):51\u201359. https:\/\/doi.org\/10.1016\/s0022-3999(02)00547-0","journal-title":"Commentary and implications J Psychosom Res"},{"issue":"2","key":"3328_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017) Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 13(2):307\u2013349. https:\/\/doi.org\/10.5664\/jcsm.6470","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"3328_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7326\/m14-2841","volume":"163","author":"JM Trauer","year":"2015","unstructured":"Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D (2015) Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med 163(3):191\u2013204. https:\/\/doi.org\/10.7326\/m14-2841","journal-title":"Ann Intern Med"},{"issue":"2","key":"3328_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.7326\/m15-2175","volume":"165","author":"A Qaseem","year":"2016","unstructured":"Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD (2016) Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 165(2):125\u2013133. https:\/\/doi.org\/10.7326\/m15-2175","journal-title":"Ann Intern Med"},{"issue":"2","key":"3328_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5664\/jcsm.8986","volume":"17","author":"JD Edinger","year":"2021","unstructured":"Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL, Sateia MJ, Troxel WM, Zhou ES, Kazmi U, Heald JL, Martin JL (2021) Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 17(2):255\u2013262. https:\/\/doi.org\/10.5664\/jcsm.8986","journal-title":"J Clin Sleep Med"},{"key":"3328_CR12","doi-asserted-by":"publisher","first-page":"215013272110140","DOI":"10.1177\/21501327211014084","volume":"12","author":"ML Perlis","year":"2021","unstructured":"Perlis ML, Pigeon WR, Grandner MA, Bishop TM, Riemann D, Ellis JG, Teel JR, Posner DA (2021) Why treat insomnia? J Prim Care Community Health 12:21501327211014084. https:\/\/doi.org\/10.1177\/21501327211014084","journal-title":"J Prim Care Community Health"},{"issue":"1","key":"3328_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jsmc.2020.11.002","volume":"16","author":"S Agnew","year":"2021","unstructured":"Agnew S, Valli\u00e8res A, Hamilton A, McCrory S, Nikolic M, Kyle SD, Fleming L, Crawford MR (2021) Adherence to cognitive behavior therapy for insomnia: an updated systematic review. Sleep Med Clin 16(1):155\u2013202. https:\/\/doi.org\/10.1016\/j.jsmc.2020.11.002","journal-title":"Sleep Med Clin"},{"issue":"1","key":"3328_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s13311-021-01010-z","volume":"18","author":"S Madari","year":"2021","unstructured":"Madari S, Golebiowski R, Mansukhani MP, Kolla BP (2021) Pharmacological management of insomnia. Neurotherapeutics 18(1):44\u201352. https:\/\/doi.org\/10.1007\/s13311-021-01010-z","journal-title":"Neurotherapeutics"},{"issue":"1","key":"3328_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/ijms17010050","volume":"17","author":"GM Asnis","year":"2015","unstructured":"Asnis GM, Thomas M, Henderson MA (2015) Pharmacotherapy treatment options for insomnia: a primer for clinicians. Int J Mol Sci 17(1):50. https:\/\/doi.org\/10.3390\/ijms17010050","journal-title":"Int J Mol Sci"},{"key":"3328_CR16","unstructured":"Ambien [package insert] (2022) Bridgewater, NJ: sanofi-aventis U.S.; February 2022"},{"key":"3328_CR17","unstructured":"Belsomra [package insert] (2023) Rahway, NJ: Merck Sharp & Dohme; February 2023"},{"key":"3328_CR18","unstructured":"Dayvigo [package insert] (2023) Nutley, NJ: Eisai Inc.; December 2023"},{"key":"3328_CR19","unstructured":"Lunesta [package insert] (2019) Marlborough, MA: Sunovion Pharmaceuticals; August 2019"},{"key":"3328_CR20","unstructured":"Quviviq [package insert] (2023) Radnor, PA: Idorsia Pharmaceuticals; October 2023"},{"key":"3328_CR21","unstructured":"Restoril [package insert] (2023) Bridgewater, NJ: Mallinckrodt Pharmaceuticals; January 2023"},{"key":"3328_CR22","unstructured":"Rozerem [package insert] (2021) Lexington, MA: Takeda Pharmaceuticals America; November 2021"},{"key":"3328_CR23","unstructured":"Silenor [package insert] (2022) Brentwood, TN: Currax Pharmaceuticals; December 2022"},{"key":"3328_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.smrv.2014.06.001","volume":"19","author":"WF Yeung","year":"2015","unstructured":"Yeung WF, Chung KF, Yung KP, Ng TH (2015) Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med Rev 19:75\u201383. https:\/\/doi.org\/10.1016\/j.smrv.2014.06.001","journal-title":"Sleep Med Rev"},{"issue":"9","key":"3328_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.sleep.2010.07.006","volume":"11","author":"T Roth","year":"2010","unstructured":"Roth T, Heith Durrence H, Jochelson P, Peterson G, Ludington E, Rogowski R, Scharf M, Lankford A (2010) Efficacy and safety of doxepin 6 mg in a model of transient insomnia. Sleep Med 11(9):843\u2013847. https:\/\/doi.org\/10.1016\/j.sleep.2010.07.006","journal-title":"Sleep Med"},{"issue":"10","key":"3328_CR26","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.5665\/sleep.1294","volume":"34","author":"AD Krystal","year":"2011","unstructured":"Krystal AD, Lankford A, Durrence HH, Ludington E, Jochelson P, Rogowski R, Roth T (2011) Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 34(10):1433\u20131442. https:\/\/doi.org\/10.5665\/sleep.1294","journal-title":"Sleep"},{"issue":"11","key":"3328_CR27","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/sleep\/33.11.1553","volume":"33","author":"AD Krystal","year":"2010","unstructured":"Krystal AD, Durrence HH, Scharf M, Jochelson P, Rogowski R, Ludington E, Roth T (2010) Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 33(11):1553\u20131561. https:\/\/doi.org\/10.1093\/sleep\/33.11.1553","journal-title":"Sleep"},{"issue":"5","key":"3328_CR28","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1185\/030079907X178874","volume":"23","author":"T Roth","year":"2007","unstructured":"Roth T, Seiden D, Wang-Weigand S, Zhang J (2007) A 2-night, 3-period, crossover study of ramelteon\u2019s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 23(5):1005\u201314","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"3328_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.sleep.2005.09.004","volume":"7","author":"M Erman","year":"2006","unstructured":"Erman M, Seiden D, Zammit G, Sainati S, Zhang J (2006) An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 7(1):17\u201324","journal-title":"Sleep Med"},{"issue":"1","key":"3328_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/JGP.0b013e3181256b01","volume":"16","author":"JK Walsh","year":"2008","unstructured":"Walsh JK, Soubrane C, Roth T (2008) Efficacy and safety of zolpidem extended release in elderly primary insomnia patients. Am J Geriatr Psychiatry 16(1):44\u201357. https:\/\/doi.org\/10.1097\/JGP.0b013e3181256b01","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"3328_CR31","doi-asserted-by":"publisher","first-page":"e1918254","DOI":"10.1001\/jamanetworkopen.2019.18254","volume":"2","author":"R Rosenberg","year":"2019","unstructured":"Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M (2019) Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open 2(12):e1918254. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18254","journal-title":"JAMA Netw Open"},{"issue":"3","key":"3328_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ana.25680","volume":"87","author":"Y Dauvilliers","year":"2020","unstructured":"Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Seboek Kinter D, Pain S, Hedner J (2020) Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. Ann Neurol 87(3):347\u2013356. https:\/\/doi.org\/10.1002\/ana.25680","journal-title":"Ann Neurol"},{"issue":"3","key":"3328_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.5664\/jcsm.27185","volume":"4","author":"MK Erman","year":"2008","unstructured":"Erman MK, Zammit G, Rubens R, Schaefer K, Wessel T, Amato D, Caron J, Walsh JK (2008) A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med 4(3):229\u201334","journal-title":"J Clin Sleep Med"},{"issue":"2","key":"3328_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7326\/m15-1781","volume":"165","author":"TJ Wilt","year":"2016","unstructured":"Wilt TJ, MacDonald R, Brasure M, Olson CM, Carlyle M, Fuchs E, Khawaja IS, Diem S, Koffel E, Ouellette J, Butler M, Kane RL (2016) Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med 165(2):103\u2013112. https:\/\/doi.org\/10.7326\/m15-1781","journal-title":"Ann Intern Med"},{"issue":"23","key":"3328_CR35","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","volume":"79","author":"WJ Herring","year":"2012","unstructured":"Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D (2012) Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79(23):2265\u20132274. https:\/\/doi.org\/10.1212\/WNL.0b013e31827688ee","journal-title":"Neurology"},{"issue":"4","key":"3328_CR36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/s0022-3999(99)00017-3","volume":"47","author":"FC Baker","year":"1999","unstructured":"Baker FC, Maloney S, Driver HS (1999) A comparison of subjective estimates of sleep with objective polysomnographic data in healthy men and women. J Psychosom Res 47(4):335\u2013341. https:\/\/doi.org\/10.1016\/s0022-3999(99)00017-3","journal-title":"J Psychosom Res"},{"issue":"1","key":"3328_CR37","doi-asserted-by":"publisher","first-page":"e14313","DOI":"10.1111\/jsr.14313","volume":"34","author":"M Perlis","year":"2025","unstructured":"Perlis M, Grandner M, Posner D, Spiegelhalder K, Riemann D (2025) Sleep diaries and other subjective measures are essential for the assessment of insomnia. J Sleep Res 34(1):e14313. https:\/\/doi.org\/10.1111\/jsr.14313","journal-title":"J Sleep Res"},{"issue":"6","key":"3328_CR38","doi-asserted-by":"publisher","first-page":"925","DOI":"10.5665\/sleep.4742","volume":"38","author":"A Winkler","year":"2015","unstructured":"Winkler A, Rief W (2015) Effect of placebo conditions on polysomnographic parameters in primary insomnia: a meta-analysis. Sleep 38(6):925\u2013931. https:\/\/doi.org\/10.5665\/sleep.4742","journal-title":"Sleep"},{"issue":"4","key":"3328_CR39","doi-asserted-by":"publisher","first-page":"e12997","DOI":"10.1111\/jsr.12997","volume":"29","author":"B Jiang","year":"2020","unstructured":"Jiang B, He D, Guo Z, Gao Z (2020) Dynamic features of placebo effects addressing persistent insomnia disorder: a meta-analysis of placebo-controlled randomized clinical trials. J Sleep Res 29(4):e12997. https:\/\/doi.org\/10.1111\/jsr.12997","journal-title":"J Sleep Res"},{"key":"3328_CR40","doi-asserted-by":"crossref","unstructured":"Reuben C, Elgaddal N, Black LI (2023) Sleep medication use in adults aged 18 and Over: United States, 2020. NCHS data brief. (462):1\u20138","DOI":"10.15620\/cdc:123013"},{"issue":"1","key":"3328_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.smrv.2010.06.004","volume":"15","author":"MM Thakkar","year":"2011","unstructured":"Thakkar MM (2011) Histamine in the regulation of wakefulness. Sleep Med Rev 15(1):65\u201374. https:\/\/doi.org\/10.1016\/j.smrv.2010.06.004","journal-title":"Sleep Med Rev"},{"issue":"4","key":"3328_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.smrv.2012.08.001","volume":"17","author":"AD Krystal","year":"2013","unstructured":"Krystal AD, Richelson E, Roth T (2013) Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications. Sleep Med Rev 17(4):263\u2013272. https:\/\/doi.org\/10.1016\/j.smrv.2012.08.001","journal-title":"Sleep Med Rev"},{"key":"3328_CR43","unstructured":"Citizens petition \u2013 DORA: Idorsia (2023) Available from: https:\/\/www.idorsia.us\/dam\/jcr:f97740c1-4fa7-43b3-9be1-69ae6296ef4d\/2023-citizens-petition-dora.pdf. Accessed 5 Sep 2024"},{"issue":"11","key":"3328_CR44","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/sleep\/30.11.1555","volume":"30","author":"T Roth","year":"2007","unstructured":"Roth T, Rogowski R, Hull S, Schwartz H, Koshorek G, Corser B, Seiden D, Lankford A (2007) Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 30(11):1555\u20131561. https:\/\/doi.org\/10.1093\/sleep\/30.11.1555","journal-title":"Sleep"},{"issue":"10","key":"3328_CR45","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.4088\/jcp.v69n1005","volume":"69","author":"M Scharf","year":"2008","unstructured":"Scharf M, Rogowski R, Hull S, Cohn M, Mayleben D, Feldman N, Ereshefsky L, Lankford A, Roth T (2008) Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 69(10):1557\u20131564. https:\/\/doi.org\/10.4088\/jcp.v69n1005","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"3328_CR46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.sleep.2011.09.006","volume":"13","author":"A Lankford","year":"2012","unstructured":"Lankford A, Rogowski R, Essink B, Ludington E, Heith Durrence H, Roth T (2012) Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med 13(2):133\u2013138. https:\/\/doi.org\/10.1016\/j.sleep.2011.09.006","journal-title":"Sleep Med"},{"issue":"3","key":"3328_CR47","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1176\/appi.neuropsych.20080206","volume":"33","author":"SH Poon","year":"2021","unstructured":"Poon SH, Quek SY, Lee TS (2021) Insomnia disorders: nosology and classification past, present, and future. J Neuropsychiatry Clin Neurosci 33(3):194\u2013200. https:\/\/doi.org\/10.1176\/appi.neuropsych.20080206","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"3328_CR48","doi-asserted-by":"crossref","unstructured":"Perlis ML, Ellis JG, Kloss JD, Riemann DW (2017) Etiology and pathophysiology of insomnia. In: Kryger M, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th ed: Elsevier, pp. 769.e4\u2013784.e4","DOI":"10.1016\/B978-0-323-24288-2.00082-9"}],"container-title":["Sleep and Breathing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-025-03328-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11325-025-03328-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-025-03328-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T13:21:07Z","timestamp":1748006467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11325-025-03328-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3328"],"URL":"https:\/\/doi.org\/10.1007\/s11325-025-03328-w","relation":{},"ISSN":["1520-9512","1522-1709"],"issn-type":[{"value":"1520-9512","type":"print"},{"value":"1522-1709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"These trials were initiated prior to introduction of clinical trial registries, so trial registration numbers are not available. Both trials were approved by an institutional review board and conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation of Good Clinical Practices; all patients gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"MF: Employee of Haleon.BF: Employee of Haleon.MA: Employee of Haleon.AK: Research Grants: Janssen Pharmaceuticals, Axsome Pharmaceutics, Attune, Eisai, Harmony, Neurocrine Biosciences, Reveal Biosensors, The Ray and Dagmar Dolby Family Fund, Weill Institute for Neurosciences, and the National Institutes of Health.Consulting: Axsome Therapeutics, Abbvie, Big Health, Eisai, Evecxia, Harmony Biosciences, Idorsia, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Neurocrine Biosciences, Neumora, Neurawell, Otsuka Pharmaceuticals, Sage, Takeda.Stock Options: Neurawell, Big\u00a0Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}